Echo IQ Deepens Mayo Clinic Pact Ahead of Potential EchoSolv HF FDA Clearance

EchoIQ Limited ( (AU:EIQ) ) has shared an update.

Echo IQ has expanded its agreement with Mayo Clinic’s non-profit Mayo Foundation to allow resale and distribution of its EchoSolv HF heart failure decision support software via the Mayo Clinic Platform – Solutions Studio, contingent on U.S. FDA clearance. The revised deal improves commercial terms, introduces an automatic renewal to potentially six years, and provides access to Mayo’s hospitals, health system network and more than 80 external partner hospitals, positioning Echo IQ for scalable U.S. deployment and revenue once regulatory approval is obtained.

The partnership follows a Mayo-led validation study in which EchoSolv HF showed high sensitivity and specificity in detecting heart failure, supporting Echo IQ’s ongoing 510(k) FDA review. With heart failure underdiagnosed in the U.S. and millions of echocardiograms performed annually, successful clearance and platform-enabled distribution could materially enhance Echo IQ’s market position, accelerate adoption of its AI within cardiac imaging workflows, and create a significant commercial opportunity across additional hospital networks and platform participants.

The most recent analyst rating on (AU:EIQ) stock is a Hold with a A$0.61 price target. To see the full list of analyst forecasts on EchoIQ Limited stock, see the AU:EIQ Stock Forecast page.

More about EchoIQ Limited

Echo IQ Limited is an Australian AI and medical technology company focused on cardiovascular diagnostics. Its flagship product, EchoSolv HF, is a clinical decision support tool designed to assist in identifying and managing heart failure from echocardiogram data, targeting the large U.S. hospital and cardiac imaging market.

Average Trading Volume: 2,764,094

Technical Sentiment Signal: Buy

Current Market Cap: A$421.3M

For detailed information about EIQ stock, go to TipRanks’ Stock Analysis page.